{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:51:38Z","timestamp":1789019498429,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.cllc.2019.11.015","type":"journal-article","created":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T11:32:59Z","timestamp":1575027179000},"page":"255-263.e4","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non\u2013Small-Cell Lung Cancer in Clinical Practice"],"prefix":"10.1016","volume":"21","author":[{"given":"Laurie E.","family":"Steffen McLouth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Thomas W.","family":"Lycan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly J.","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Gabbard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7242-3315","authenticated-orcid":false,"given":"Jimmy","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Farris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan C.","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas M.","family":"Pajewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E.","family":"Weaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Jeffrey","family":"Petty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2019.11.015_bib1","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2019.11.015_bib2","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1\u2013positive, advanced non\u2013small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2019.11.015_bib3","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1200\/JCO.2017.74.3062","article-title":"Nivolumab versus docetaxel in previously treated patients with advanced non\u2013small-cell lung cancer: two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057)","volume":"35","author":"Horn","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2019.11.015_bib4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","article-title":"Atezolizumab versus docetaxel in patients with previously treated non\u2013small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2019.11.015_bib5","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non\u2013small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2019.11.015_bib6","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2019.11.015_bib7","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2019.11.015_bib8","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJMp0911494","article-title":"The missing voice of patients in drug-safety reporting","volume":"362","author":"Basch","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 2","key":"10.1016\/j.cllc.2019.11.015_bib9","doi-asserted-by":"crossref","first-page":"S125","DOI":"10.1111\/j.1524-4733.2007.00275.x","article-title":"Patient-reported outcomes to support medical product labeling claims: FDA perspective","volume":"10","author":"Patrick","year":"2007","journal-title":"Value Health"},{"key":"10.1016\/j.cllc.2019.11.015_bib10","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00432-016-2335-9","article-title":"Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting","volume":"143","author":"Atkinson","year":"2017","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.cllc.2019.11.015_bib11","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1093\/jnci\/djp386","article-title":"Adverse symptom event reporting by patients vs. clinicians: relationships with clinical outcomes","volume":"101","author":"Basch","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cllc.2019.11.015_bib12","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jtho.2019.01.016","article-title":"Health-related quality of life in KEYNOTE-010: a phase II\/III study of pembrolizumab versus docetaxel in patients with previously treated advanced,programmed death ligand-1 expressing NSCLC","volume":"14","author":"Barlesi","year":"2019","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.11.015_bib13","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S1470-2045(17)30690-3","article-title":"Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1\u2013positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial","volume":"18","author":"Brahmer","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2019.11.015_bib14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cllc.2018.05.011","article-title":"Patient-reported outcomes in OAK: a phase III study of atezolizumab versus docetaxel in advanced non\u2013small-cell lung cancer","volume":"19","author":"Bordoni","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.cllc.2019.11.015_bib15","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jtho.2017.10.029","article-title":"Impact of nivolumab versus docetaxel on health-related quality of life and symptoms in patients with advanced squamous non\u2013small cell lung cancer: Results from the CheckMate 017 study","volume":"13","author":"Reck","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"issue":"15 suppl","key":"10.1016\/j.cllc.2019.11.015_bib16","doi-asserted-by":"crossref","first-page":"9021","DOI":"10.1200\/JCO.2018.36.15_suppl.9021","article-title":"Health-related quality of life (HRQoL) in the KEYNOTE-189 study of pembrolizumab (pembro) or placebo (pbo)+ pemetrexed (pem)\u00a0+ platinum (plt) for metastatic NSCLC","volume":"36","author":"Garassino","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2019.11.015_bib17","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jpainsymman.2019.03.015","article-title":"Patient reported outcomes for cancer patients receiving immunotherapy: opportunities for palliative care\u2014a systematic review","volume":"58","author":"Hall","year":"2019","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.cllc.2019.11.015_bib18","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1177\/1740774519836991","article-title":"Patient reported outcomes in anti\u2013PD-1\/PD-L1 inhibitor immunotherapy registration trials: FDA analysis of data submitted and future directions","volume":"16","author":"King-Kallimanis","year":"2019","journal-title":"Clin Trials"},{"key":"10.1016\/j.cllc.2019.11.015_bib19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/JTO.0b013e3181622c17","article-title":"Prevalence of poor performance status in lung cancer patients: implications for research","volume":"3","author":"Lilenbaum","year":"2008","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.11.015_bib20","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/JTO.0b013e3180311792","article-title":"Many patients 80 years and older with advanced non\u2013small cell lung cancer (NSCLC) can tolerate chemotherapy","volume":"2","author":"Altundag","year":"2007","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2019.11.015_bib21","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.lungcan.2017.11.008","article-title":"Does nivolumab for progressed metastatic lung cancer fulfill its promises? An efficacy and safety analysis in 20 general hospitals","volume":"115","author":"Tournoy","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2019.11.015_bib22","series-title":"Designing and Conducting Mixed Methods Research","author":"Creswell","year":"2017"},{"key":"10.1016\/j.cllc.2019.11.015_bib24","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1002\/cncr.29964","article-title":"Cognitive testing of tobacco use items for administration to patients with cancer and cancer survivors in clinical research","volume":"122","author":"Land","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2019.11.015_bib25","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.cllc.2019.11.015_bib26","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A\u00a0new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J\u00a0Chronic Dis"},{"key":"10.1016\/j.cllc.2019.11.015_bib27","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.cllc.2019.11.015_bib28","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1093\/jnci\/85.5.365","article-title":"The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology","volume":"85","author":"Aaronson","year":"1993","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cllc.2019.11.015_bib29","doi-asserted-by":"crossref","first-page":"dju244","DOI":"10.1093\/jnci\/dju244","article-title":"Development of the National Cancer Institute\u2019s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)","volume":"106","author":"Basch","year":"2014","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cllc.2019.11.015_bib30","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/jamaoncol.2015.2639","article-title":"Validity and reliability of the US National Cancer Institute\u2019s patient-reported outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)","volume":"1","author":"Dueck","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.cllc.2019.11.015_bib31","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1200\/JCO.1998.16.1.139","article-title":"Interpreting the significance of changes in health-related quality-of-life scores","volume":"16","author":"Osoba","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2019.11.015_bib32","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.23157","article-title":"Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review","volume":"112","author":"Ford","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2019.11.015_bib33","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.2217\/imt-2017-0108","article-title":"Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review","volume":"9","author":"Abdel-Rahman","year":"2017","journal-title":"Immunotherapy"},{"key":"10.1016\/j.cllc.2019.11.015_bib34","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2019.11.015_bib35","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.cllc.2019.11.015_bib36","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1440-1843.2012.02282.x","article-title":"Prevalence of undiagnosed and undertreated chronic obstructive pulmonary disease in lung cancer population","volume":"18","author":"Zhang","year":"2013","journal-title":"Respirology"},{"key":"10.1016\/j.cllc.2019.11.015_bib37","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3109\/0284186X.2014.1001496","article-title":"Prevalence and management of pulmonary comorbidity in patients with lung and head and neck cancer","volume":"54","author":"Gottlieb","year":"2015","journal-title":"Acta Oncol"},{"key":"10.1016\/j.cllc.2019.11.015_bib38","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","journal-title":"Am J Clin Dermatol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730419303328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730419303328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:10:44Z","timestamp":1761505844000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730419303328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S1525730419303328"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2019.11.015","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non\u2013Small-Cell Lung Cancer in Clinical Practice","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2019.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}